| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2141.1995.TB08366.X |
| P698 | PubMed publication ID | 7734357 |
| P2093 | author name string | Danø K | |
| Høyer-Hansen G | |||
| Rønne E | |||
| Plesner T | |||
| Pappot H | |||
| Grøndahl-Hansen J | |||
| Hansen NE | |||
| P2860 | cites work | Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria | Q28269484 |
| The Cloning of PIG-A, a Component in the Early Step of GPI-Anchor Biosynthesis | Q28297787 | ||
| The urokinase receptor: involvement in cell surface proteolysis and cancer invasion | Q35240620 | ||
| Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse | Q36210147 | ||
| A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase | Q36211634 | ||
| Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria | Q36361263 | ||
| Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins | Q37423113 | ||
| Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors | Q39508019 | ||
| Cerebral venous thrombosis in paroxysmal nocturnal hemoglobinuria: report of two cases | Q40894967 | ||
| A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria | Q41085646 | ||
| The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds | Q41475599 | ||
| Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor | Q41669188 | ||
| Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract | Q41877722 | ||
| Autocrine saturation of pro-urokinase receptors on human A431 cells. | Q50579055 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 576-581 | |
| P577 | publication date | 1995-03-01 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria | |
| P478 | volume | 89 |
| Q33974535 | Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice |
| Q92891837 | Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH) |
| Q47896134 | Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay |
| Q74217799 | Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria |
| Q48211364 | Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development |
| Q73685074 | Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients |
| Q33800427 | Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab |
| Q42995635 | Evidence that the inhibition of cartilage proteoglycan breakdown by mannosamine is not mediated via inhibition of glycosylphosphatidylinositol anchor formation |
| Q36158746 | Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients |
| Q38189275 | Involvement of urokinase-type plasminogen activator system in cancer: an overview |
| Q90484775 | Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry |
| Q63753602 | Loss of ELISA specificity due to biotinylation of monoclonal antibodies |
| Q42783308 | Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria |
| Q37955206 | Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria |
| Q54960825 | Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. |
| Q34431429 | Paroxysmal nocturnal hemoglobinuria |
| Q40475372 | Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. |
| Q33578860 | Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees |
| Q50171786 | Proteinase 3 expression on the neutrophils of patients with paroxysmal nocturnal hemoglobinuria |
| Q35126938 | Recent advances in the bcr-abl negative chronic myeloproliferative diseases |
| Q34658557 | Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy |
| Q35548720 | Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis |
| Q36619635 | Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. |
| Q40978037 | Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia |
| Q40701611 | The cleavage of the urokinase receptor regulates its multiple functions |
| Q44941578 | The platelet function defect of paroxysmal nocturnal haemoglobinuria |
| Q28257803 | The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling |
| Q26853483 | Thrombosis in paroxysmal nocturnal hemoglobinuria |
| Q79358883 | Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion |
| Q43000092 | Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. |
Search more.